Research programme: molecular chaperone regulators - CytRx

Drug Profile

Research programme: molecular chaperone regulators - CytRx

Latest Information Update: 12 May 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biorex
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neurological disorders

Most Recent Events

  • 07 May 2010 Preclinical development is ongoing in USA
  • 13 Oct 2004 Biorex has been acquired by CytRx Corporation
  • 15 Mar 2004 A preclinical study has been added to the neurological disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top